11 
"manipulations” in humans now possible by use of techniques such 
as rDNA technology, are controversial. Their potential human 
consequences raise questions regarding the socially responsible 
use of this new technology. What position should the 
Pharmaceutical Manufacturers Association (PMA) take in order to 
ensure continued use and development of this technology by the 
pharmaceutical industry, but -at the same time to provide for 
appropriate guidelines or regulatory controls and a thorough 
public discussion relative to the socially responsible use of 
this technology? 
This report, in four parts, presents the PMA position. 
The first part will define biotechnology and discuss some of its 
potential uses in the pharmaceutical industry. The second part 
will consider the guidelines and other regulations of rDNA 
technology in the United States. Part three will deal with the 
social and ethical questions arising from use of this 
technology. The final part will balance benefits versus 
concerns and set forth a Pharmaceutical Manufacturers 
Association position. 
[601] 
